- Olympus shares fell as much as 17% in Tokyo, the steepest decline since April 2025.
- The FDA warning letter follows inspections of six facilities conducted in late 2025 and cites quality management system and process observations.
- Olympus said the warning will not disrupt production and is not expected to affect financial results.
- Olympus is set to respond to the FDA within 15 business days of receiving the warning letter.
Quotes
“The warning will not disrupt production and it is not expected to impact financial results”